Financial Performance - Consolidated net sales for Q1 FY 2026 were $120.5 million, a 6% decrease from $127.9 million in Q1 FY 2025[4] - Net income for Q1 FY 2026 was $15.5 million, down 6% from $16.4 million in the same period last year[13] - EBITDA for Q1 FY 2026 totaled $23.6 million, reflecting a 10% decrease compared to $26.2 million in Q1 FY 2025[11] - The B2B Products Group reported revenues of $44.3 million, a 9% decline from the prior year's record levels[15] - The R&W Products Group's revenues were $76.2 million, down 4% from the previous year's record, driven by a decline in volume[17] - Gross profit for Q1 FY 2026 was $35.5 million, representing a 13% decline from the prior year, with gross margins at 29.5%[8] - Net sales for the three months ended October 31, 2025, were $120,486, a decrease of 5.7% compared to $127,945 in the same period of 2024[31] - Gross profit margin decreased to 29.5% in Q1 2025 from 31.9% in Q1 2024, with gross profit amounting to $35,495 compared to $40,780[31] - Net income for Q1 2025 was $15,456, a decline of 5.6% from $16,376 in Q1 2024, maintaining a net income margin of 12.8%[31] - EBITDA for Q1 2025 was $23,641, down from $26,167 in Q1 2024, indicating a decline of 9.7%[37] Expenses and Liabilities - Selling, general and administrative expenses decreased by 5% to $18.5 million compared to $19.6 million in the same period last year[9] - Operating income for the B2B Products Group was $13.6 million, down 20% from $17.1 million in Q1 FY 2025[16] - Total current assets decreased to $170,076 as of October 31, 2025, from $177,383 as of July 31, 2025[33] - Total liabilities decreased to $114,196 as of October 31, 2025, from $132,617 as of July 31, 2025[33] Cash Flow and Dividends - Cash and cash equivalents at the end of Q1 FY 2026 totaled $42.4 million, down from $50.5 million at the end of FY 2025[14] - Cash and cash equivalents decreased to $42,384 from $50,458, reflecting a net decrease of $8,074 in cash during the quarter[35] - The company paid dividends of $2,444 in Q1 2025, compared to $2,096 in Q1 2024, representing an increase of 16.6%[35] - The company reported a decrease in accounts receivable by $3,077, improving cash flow from operations[35] Sales Performance - Domestic cat litter sales, excluding co-packaging, were $56.2 million, a 6% decline year-over-year[18] - Cash and cash equivalents decreased to $42,384 from $50,458, reflecting a net decrease of $8,074 in cash during the quarter[35] - The book value per share outstanding increased to $19.14 from $18.76, reflecting a growth of 2.0%[33]

Clinical Trials and Research - MiNK Therapeutics reported a median overall survival of approximately 23 months for patients receiving agenT-797 in combination with PD-1 therapies, significantly exceeding the expected survival of under six months in a refractory setting [7]. - The company observed a complete remission in a patient with metastatic testicular cancer lasting over two years following a single infusion of agenT-797 combined with PD-1 blockade [26]. - The company is preparing for a global Phase II trial in acute pulmonary dysfunction, with the study expected to launch within weeks [19]. - The Phase I study of agenT-797 demonstrated durable activity across various tumor types, with nearly half of patients having failed PD-1 ligand inhibitors [25]. - The primary endpoint for the pulmonary disease trial will be 28-day mortality, with additional secondary and exploratory endpoints being established [71]. - The company anticipates launching the severe pulmonary disease trial with the first patient targeted for enrollment by early Q1 of next year [54]. - The GvHD trial is funded through a partnership with government collaborators and aims to improve engraftment success without the need for cytotoxic lymphodepletion [60]. - The GvHD program aims for a significant reduction in GvHD incidence, targeting a 50% improvement or more, which would be substantially beneficial [63]. - MiNK Therapeutics aims to redefine immune recovery in cancer and critical illness, focusing on reeducating the immune system rather than suppressing it [35]. - The company is actively engaging with the FDA to ensure rapid development pathways for its clinical programs [64]. Financial Performance - The cash balance at the end of Q3 2025 was $14.3 million, with an additional $1.2 million raised since the quarter end, providing a runway through 2026 [36]. - The net loss for Q3 2025 was $2.9 million, or $0.65 per share, compared to a net loss of $1.8 million, or $0.46 per share, for Q3 2024 [36]. - For the nine months ended September 30, 2025, the net loss was $9.9 million or $2.39 per share, compared to a net loss of $8.3 million or $2.24 per share for the same period in 2024 [38]. - The company executed an at-the-market sales agreement, leveraging a more than 700% increase in equity price, which extended the cash runway through 2026 [42]. - The company is exploring nondilutive financing options to expand its manufacturing infrastructure beyond current capabilities [76]. Partnerships and Collaborations - The company has established a strategic partnership with the University of Wisconsin to advance its iNKT program in immune reconstitution following stem cell transplantation [15]. - The company is leveraging public-private partnerships, including support from the Department of Defense and NIH, to advance its clinical programs with minimal capital impact [17]. - Discussions are ongoing with collaborators in both the private and public sectors to leverage substantial scale and interest [79]. Manufacturing and Production - The company is currently able to produce 1 billion cells per donor, which provides substantial cost advantages and the ability to stockpile materials for trials [76]. - The cells have demonstrated stability for almost 3 years, indicating potential for continued production at scale [77]. - The company is preparing for future opportunities based on the current stability of their products [77].

EXHIBIT 99.1 Yext Announces Third Quarter Fiscal 2026 Results NEW YORK -- (BUSINESS WIRE) — December 8, 2025 — Yext, Inc. (NYSE: YEXT), the leading brand visibility platform, today announced its results for the three months ended October 31, 2025, or Yext's third quarter of fiscal year 2026. The Yext Board of Directors and its Special Committee continues to work with its advisors to carefully review and consider Michael Walrath's non-binding proposal to acquire the company, as well as any other strategic al ...

Financial Performance - Net sales for the three months ended October 31, 2025, were $120.486 million, a decrease of 5.7% compared to $127.945 million for the same period in 2024[15] - Gross profit for the same period was $35.495 million, down 13.5% from $40.780 million year-over-year[15] - Net income for the three months ended October 31, 2025, was $15.456 million, a decline of 5.6% compared to $16.376 million in the prior year[15] - Earnings per share for common stock were $1.14 for the three months ended October 31, 2025, compared to $1.21 for the same period in 2024, reflecting a decrease of 5.8%[15] - Operating income for the three months ended October 31, 2025, was $26.033 million, down from $30.487 million in the prior year[80] - The Business to Business Products Group reported net sales of $44,286,000 for the three months ended October 31, 2025, down from $48,415,000 in 2024, a decrease of 4.7%[80] - The Retail and Wholesale Products Group achieved net sales of $76,200,000 for the three months ended October 31, 2025, compared to $79,530,000 in 2024, a decline of 4.4%[80] Assets and Liabilities - Total assets as of October 31, 2025, were $380.723 million, down from $391.677 million as of July 31, 2025, representing a decrease of 2.4%[11] - Total liabilities decreased to $114.196 million as of October 31, 2025, from $132.617 million as of July 31, 2025, a reduction of 13.9%[14] - Stockholders' equity increased to $266.527 million as of October 31, 2025, compared to $259.060 million as of July 31, 2025, an increase of 2.9%[14] - Cash and cash equivalents at the end of the period totaled $42,384,000, an increase from $13,506,000 year-over-year[25] - Cash equivalents decreased to $28.6 million as of October 31, 2025, down from $35.3 million as of July 31, 2025[59] - The estimated fair value of debt was $40.8 million as of October 31, 2025, slightly up from $40.3 million as of July 31, 2025[61] Dividends and Shareholder Returns - Dividends declared per share for common stock increased to $0.180 from $0.155 year-over-year, reflecting a growth of 16.1%[15] - Dividends paid during the period amounted to $2,444,000, an increase of 16.6% from $2,096,000 in the previous year[22] - The company declared dividends of $0.180 per share for Common Stock and $0.135 per share for Class B Stock for the three months ended October 31, 2025[15] Cash Flow and Expenditures - Net cash provided by operating activities was $10,349,000, down from $10,919,000, reflecting a decrease of 5.2%[22] - Capital expenditures for the period were $9,066,000, a reduction of 29.5% compared to $12,817,000 in the previous year[22] - The company experienced a net decrease in cash and cash equivalents of $8,074 thousand for the three months ended October 31, 2025, compared to a decrease of $10,975 thousand in the same period of 2024[22] Stock and Compensation - Average shares outstanding for diluted common stock increased to 13.927 million for the three months ended October 31, 2025, compared to 13.811 million in the prior year[15] - Stock-based compensation expense increased to $1.1 million for the three months ended October 31, 2025, from $0.9 million in the same period of 2024[84] - The total number of non-vested restricted stock outstanding as of October 31, 2025, was 611,000 shares, with a weighted average grant date fair value of $33.31 per share[85] Inventory and Receivables - Accounts receivable as of October 31, 2025, was $66,500,000, compared to $62,200,000 as of July 31, 2024, indicating a year-over-year increase of 7.4%[35] - Total inventories increased to $56.645 million as of October 31, 2025, compared to $51.594 million as of July 31, 2025, with finished goods valued at $32.214 million[58] Operating Segments and Expenses - Selling, general and administrative expenses (SG&A) include various costs such as salaries, marketing, and research and development, impacting overall profitability[48] - The company has two reportable operating segments: Retail and Wholesale Products Group, and Business to Business Products Group, with distinct customer bases and product offerings[77] Accounting and Compliance - The company is currently evaluating the impact of recently issued accounting standards on its financial disclosures, including ASU No. 2023-09 and ASU No. 2024-03[51][52] - The company has adopted new accounting standards requiring enhanced disclosures about significant segment expenses and income tax information[50][51]

Financial Performance - Net sales increased by approximately 50% to $47.3 million for the three months ended October 31, 2025, compared to $31.5 million for the same period in 2024, primarily due to the acquisition of Crown 1, which contributed approximately $10.0 million in net sales[129] - For the nine months ended October 31, 2025, net sales increased by approximately 31% to $117.7 million from $89.7 million in the same period in 2024, with the Crown 1 acquisition contributing approximately $10.0 million[135] - The company reported net income of approximately $3.1 million for the nine months ended October 31, 2025, compared to $2.1 million for the same period in 2024[134] Cost and Expenses - Costs of sales rose by approximately 48% to $36.1 million, or 76% of net sales, during the three months ended October 31, 2025, compared to $24.4 million, or 77% of net sales, in the prior year[130] - Operating expenses increased by approximately $6.5 million for the nine months ended October 31, 2025, primarily due to payroll, professional fees, and advertising expenses[139] - Gross profit margin improved to 24% for the three months ended October 31, 2025, compared to 23% for the same period in 2024, driven by operational efficiencies[131] Cash Flow and Working Capital - Net cash provided by operating activities for the nine months ended October 31, 2025, was approximately $8.2 million, up from $6.0 million in the same period in 2024[143] - Net cash used in investing activities for the nine months ended October 31, 2025, was approximately $18.7 million, primarily for the purchase of Crown 1 and fixed assets[145] - Net cash provided by financing activities for the nine months ended October 31, 2025, was approximately $21.5 million, consisting of net proceeds from the sale of common stock and proceeds from the Crown Note[147] - Working capital increased to approximately $18.8 million as of October 31, 2025, compared to $4.9 million as of January 31, 2025, primarily due to an increase in cash and cash equivalents[141] Debt and Financing - As of October 31, 2025, the company had approximately $5.9 million outstanding under its Term Loan Agreement with M&T Bank, with a maturity date of October 1, 2030[149] - The outstanding balance of the T&L Note was approximately $0 as of October 31, 2025, compared to $2.9 million as of January 31, 2025[154] - The company believes its cash resources will be sufficient to meet cash requirements for at least the next twelve months, but may require additional funding for growth or strategic objectives[150] Sensitivity Analysis - A 1% change in the effective interest rate applied to the T&L Note would result in a pre-tax interest expense fluctuation of approximately $59 thousand on an annualized basis[154] - A 1.0% increase in commodity prices would negatively impact costs of sales by approximately $945 thousand on an annualized basis[156]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended: October 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from ___________ to ____________ Commission File Number: 001-40597 Mama's Creations, Inc. (Exact name of Registrant as specified in its charter) (State or other jur ...

Financial Performance - The company reported a significant increase in revenue, with a year-over-year growth rate of 25% in Q3 2026[2] - The company anticipates continued growth, projecting a revenue increase of 20% for the next quarter[2] - New product launches are expected to contribute an additional $50 million in revenue over the next fiscal year[2] - Operating expenses increased by 12%, primarily due to higher marketing costs associated with new product launches[2] - The company reported a net loss of $5 million for the quarter, reflecting ongoing investments in growth initiatives[2] User Growth - User data indicates a 15% increase in active subscriptions, reaching a total of 1.5 million users[2] Market Expansion - Market expansion efforts have led to a 10% increase in market share in the North American region[2] - The company is exploring potential acquisitions to bolster its technology portfolio and market presence[2] Investment in Technology - The company is investing $30 million in research and development to enhance its data security solutions[2] Risk Factors - Risk factors include potential challenges in customer retention and competition in the data security market[2] - Recent rapid growth may not indicate future growth, making it difficult to evaluate future prospects[17] - The company has a history of operating losses and may not achieve or sustain profitability in the future[17] - If customers do not renew or expand their subscriptions, future results of operations could be harmed[17] - The reliance on third-party cloud providers poses risks that could adversely affect business and financial condition[17] - The competitive market environment may hinder the company's ability to grow effectively[17] - Estimates of market opportunity and growth forecasts may prove to be inaccurate, impacting business growth[17] - The dual class structure of common stock concentrates voting control, limiting influence on corporate matters[17]

Financial Performance - Byrna Technologies reported preliminary fiscal fourth quarter revenues of $35.1 million, a 26% increase from $28.0 million in the same quarter of fiscal 2024[2]. - Full-year revenues for 2025 are expected to reach $118.0 million, up 38% from $85.8 million in fiscal year 2024[2]. - The fourth quarter revenue growth was driven by strong dealer and chain store performance, with direct-to-consumer and international channels also contributing significantly[3]. - The sales breakdown for Q4 2025 showed web sales at $22.3 million (up 7%), chain stores and dealers at $8.4 million (up 68%), and international sales at $3.5 million (up 91%) compared to Q4 2024[7]. Cash Position and Stock Repurchase - Byrna's cash and cash equivalents increased to over $15 million as of November 30, 2025, compared to $9.0 million at the end of August 2025[4]. - During the quarter, Byrna repurchased more than $1.0 million of common stock[5]. Product Development and Market Strategy - Byrna introduced the Byrna CL, its most advanced launcher to date, which contributed to the strong performance in 2025[6]. - The company aims to further normalize the Byrna brand and elevate the less-lethal category within the personal safety market in 2026[6]. Future Outlook - Byrna plans to report full financial results for the fiscal fourth quarter in February, accompanied by a conference call for investors and analysts[8]. - Forward-looking statements indicate expectations for continued sales growth and brand visibility efforts, though they are subject to various risks and uncertainties[10].

Financial Performance - Total revenue for Q3 Fiscal 2026 was $120.3 million, representing a 13% year-over-year increase[7] - Net income for the quarter was $4.3 million, compared to a net loss of $14.4 million in the same period last year[7] - Adjusted EBITDA for the quarter was $29.1 million, compared to $9.8 million in the same period last year[7] - Total revenues for the three months ended October 31, 2025, were $120.3 million, a 12.5% increase from $106.8 million in the same period of 2024[28] - Net income for the three months ended October 31, 2025, was $4.3 million, compared to a net loss of $14.4 million in the same period of 2024[28] - Operating income improved to $3.7 million from a loss of $13.8 million year-over-year[28] - Adjusted EBITDA for the three months ended October 31, 2025, was $29,149,000, compared to $9,769,000 for the same period in 2024, representing a significant increase[41] - Free cash flow for the three months ended October 31, 2025, was $8,801,000, compared to $1,603,000 for the same period in 2024, demonstrating improved cash generation capabilities[44] - Net income for the three months ended October 31, 2025, was $4,271,000, a significant improvement from a net loss of $14,403,000 in the same period of 2024[41] Client Metrics - Average number of healthcare services clients (AHSCs) increased to 4,520, up 7% year-over-year[7] - The company expects AHSCs for fiscal 2026 to be approximately 4,515, including 15 AHSCs from the AccessOne acquisition[12] - The average number of healthcare services clients (AHSCs) increased to 4,520 in the three months ended October 31, 2025, up from 4,237 in the same period of 2024, indicating growth in client acquisition[48] - Total revenue per AHSC for the three months ended October 31, 2025, was $26,622, compared to $25,207 for the same period in 2024, reflecting a year-over-year increase of 5.6%[48] Revenue Outlook - The company updated its revenue outlook for fiscal 2026 to a range of $479 million to $481 million, including approximately $7.5 million from AccessOne[10] - For fiscal 2027, the company anticipates revenue in the range of $545 million to $559 million, a 14-16% increase over fiscal 2026[13] Acquisition and Investment - The AccessOne acquisition was completed for approximately $160 million, enhancing the company's financing solutions for healthcare receivables[4] - Research and development expenses were $29.5 million, consistent with $29.3 million in the prior year, indicating stable investment in innovation[28] - Capitalized internal-use software development costs for the three months ended October 31, 2025, were $3,395,000, compared to $3,566,000 in the same period of 2024, indicating a stable investment in technology[44] Cash and Assets - Cash and cash equivalents as of October 31, 2025, were $106.4 million, an increase of $22.2 million from January 31, 2025[7] - Cash and cash equivalents increased to $106.4 million as of October 31, 2025, compared to $81.7 million at the end of the previous year[32] - Total current assets rose to $240.9 million, a 18.5% increase from $203.3 million as of January 31, 2025[26] Liabilities and Expenses - Total liabilities decreased to $103.1 million from $123.6 million, reflecting a reduction of 16.6%[26] - GAAP operating expenses for the three months ended October 31, 2025, totaled $89,427,000, down from $96,873,000 in the same period of 2024, indicating cost management efforts[46] - Stock-based compensation expense for the three months ended October 31, 2025, was $15,959,000, slightly lower than $16,525,000 in the same period of 2024, reflecting a controlled approach to compensation[46] Payment Metrics - Patient payment volume reached $1,181 million in the three months ended October 31, 2025, compared to $1,081 million in the same period of 2024, showing a growth of 9.3%[51] - The payment facilitator volume percentage increased to 85% in the three months ended October 31, 2025, up from 81% in the same period of 2024, indicating a higher reliance on the payment facilitation services[51]

Revenue and Growth - Revenue for 2024 was $8.7 billion, with over 70% generated outside the United States, and TOMMY HILFIGER and Calvin Klein brands accounted for over 95% of total revenue [168]. - For the full year 2025, the company anticipates revenue growth in low single-digits, including a positive impact from foreign currency translation [204]. - The company expects Q4 2025 revenue to increase slightly in low single-digits compared to Q4 2024, with a positive impact from foreign currency translation [203]. - For the thirty-nine weeks ended November 2, 2025, total revenue was $6.445 billion, a 3% increase from $6.281 billion in the prior year [200]. - Total revenue for Q3 2025 was $2.294 billion, a 2% increase from $2.255 billion in Q3 2024, with a 3% positive impact from foreign currency translation [185]. Profitability and Margins - Gross profit for the same period decreased by 2% to $1.293 billion, with a gross margin of 56.3%, down 210 basis points from the previous year [184]. - Gross profit in Q3 2025 was $1.293 billion, or 56.3% of total revenue, down from $1.317 billion, or 58.4% in Q3 2024, primarily due to tariffs and a shift to lower-margin wholesale business [189]. - The company expects gross margin for the full year 2025 to decrease by approximately 250 basis points compared to 2024, including an 80 basis point negative impact from tariffs [208]. - Net income for the thirteen weeks ended November 2, 2025, was $4 million, a significant decrease from $132 million in the prior year [184]. - Income before interest and taxes in Q3 2025 was $181 million, or 7.9% of total revenue, down from $183 million, or 8.1% in Q3 2024 [195]. Expenses and Cost Management - SG&A expenses in Q3 2025 were $1.121 billion, or 48.9% of total revenue, compared to $1.154 billion, or 51.2% in Q3 2024, reflecting a 230 basis point decrease [190]. - SG&A expenses for the thirty-nine weeks ended November 2, 2025, were $3.274 billion, or 50.8% of total revenue, a decrease of 100 basis points from the prior year [209]. - A multiyear initiative aimed at simplifying the operating model is expected to yield annual cost savings of approximately $200 million to $300 million by 2026 [176]. Tax and Impairment Charges - The effective tax rate for the same period was 97.4%, compared to 21.0% in the previous year, indicating a substantial increase in tax expense [184]. - The effective income tax rate for Q3 2025 was 97.4%, significantly higher than 21.0% in Q3 2024, due to non-deductible impairment charges [197][198]. - The effective income tax rate for the thirty-nine weeks ended November 2, 2025, was 335.1%, significantly higher than the prior year due to non-deductible impairment charges [224]. - The company recorded pre-tax noncash goodwill and other intangible impairment charges of $480 million in Q1 2025 due to increased discount rates [176]. - Noncash impairment charges of $480 million were recorded in the first quarter of 2025, including $426 million related to goodwill [212]. International Operations - Approximately 6% of revenue and 20% of income before interest and taxes were generated in China in 2024, with potential adverse effects from being placed on the List of Unreliable Entities [181]. - APAC revenue decreased by $61 million, or 5%, due to declines in both direct-to-consumer and wholesale businesses amid a challenging consumer environment [206]. Cash Flow and Capital Management - Cash and cash equivalents at November 2, 2025, were $158 million, a decrease of $590 million from $748 million at February 2, 2025 [230]. - Cash provided by operating activities decreased to $97 million for the thirty-nine weeks ended November 2, 2025, down from $254 million for the same period in 2024, primarily due to a decrease in net income adjusted for noncash charges [233]. - Capital expenditures for the thirty-nine weeks ended November 2, 2025, were $98 million, compared to $115 million in the same period in 2024, with expectations for full-year 2025 capital expenditures to be flat at approximately $159 million [239]. - The company completed the sale of its women's intimates businesses for net proceeds of $156 million on November 27, 2023, with an additional $10 million received in quarterly installments through the first quarter of 2025 [236]. Debt and Financing - Long-term debt increased to $2.246 billion as of November 2, 2025, from $1.654 billion as of November 3, 2024 [245]. - The company expects to make total long-term debt repayments of approximately $13 million for the full year 2025 [257]. - The company has not drawn on its $250 million delayed draw term loan facility as of November 2, 2025, which remains available for borrowing [251]. - The company issued $500 million principal amount of 5 1/2% senior notes due June 13, 2030, with $6 million in fees amortized over the term of the notes [265]. - The company ended the third quarter of 2025 with approximately $1.7 billion of borrowing capacity available under various debt facilities [230]. Shareholder Returns - The company has authorized a $5 billion stock repurchase program, with $1.212 billion remaining available for future repurchases as of November 2, 2025 [241][243]. - The company entered into ASR agreements to repurchase $500 million of its shares, acquiring approximately 6.9 million shares at an average price of $72.44 per share [242]. - Cash dividends paid on common stock totaled $6 million for both the thirty-nine weeks ended November 2, 2025, and November 3, 2024, with projected total dividends for 2025 expected to be approximately $7 million [240]. Currency and Foreign Exchange - The company expects 2025 revenue and net income to increase by approximately $200 million and $20 million, respectively, due to foreign currency translation [275]. - Favorable foreign currency translation adjustments of $294 million were recognized during the thirty-nine weeks ended November 2, 2025, primarily due to an 11% weakening of the U.S. dollar against the euro [276]. - A 10% change in foreign currency exchange rates against the U.S. dollar would result in a change in the fair value of foreign currency forward contracts of approximately $110 million [279]. - The effect of a 10% change in the euro against the U.S. dollar would result in a change in the fair value of net investment hedges of approximately $180 million [281].